35 results about "Pregnancy outcomes" patented technology

The invention discloses a serum/blood plasma polypeptide marker related to gestational diabetes mellitus auxiliary early diagnosis and application thereof. The serum/blood plasma polypeptide marker ischaracterized in that the marker is selected from arbitrary one or more polypeptides of Q6PFW1, P35658, P32004 and Q9Y4H2. The serum/blood plasma polypeptide marker serving as a detection target is applied to preparation of gestational diabetes mellitus auxiliary early diagnosis reagents. The expression quantity of the marker for detecting pregnancy serum/blood plasma can be used in GDM auxiliaryearly diagnosis. Support is provided to clinical doctors for accurately predicting the GDM pathogenesis outcome of pregnancy and timely adopting personal prevention and treatment schemes, so that theoccurrence rate of GDM can be furthest reduced, and adverse pregnancy outcomes can be reduced.

The invention provides serum-based, diagnostic, biological assays for predicting disorders of pregnancy resulting from poor trophoblast and/or placental ischemia, including preeclampsia. Serum samples from such subjects exhibit an ability to disrupt the architecture involving fetal trophoblasts and maternal endothelial cells in a three-dimensional, dual cell co-culture system provided herein, in contrast to normal pregnancy serum samples. Based on these distinctions, the assays are employed to predict pregnancy outcomes as early as first trimester.

The invention relates to a method of assessing pregnancy outcome. The inventors investigated endometrial miRNAs associated with pregnancy outcome by studying miRNAs associated with endometrial receptivity, implantation failure and embryo miscarriage. They performed a miRNomic study to find miRNAs that are differentially expressed according to the endometrial receptivity status, compared the endometrial miRNome between receptive patients with negative beta-hCG and receptive patients with positive beta-hCG, and compared the endometrial miRNome between receptive patients with a miscarriage between 8-12 weeks of amenorrhoea and receptive patients with a live birth. They demonstrated miRNA differential expression in endometrial samples according to the pregnancy outcome. Thus, the invention relates to a method of assessing pregnancy outcome of a patient, comprising a step of measuring in a biological sample obtained from said patient the expression level of at least one miRNA selected from the group consisting of miR-455-3p, miR-4423-3p, miR-4445-3p, miR-3128, miR-3201, let-7b-5p, let-7c-5p, miR-4534, miR-214-3p, miR-15b-5p, miR-424-3p, miR-181a-5p, miR-574-3p, miR-92a-3p, miR-320c, let-7d-5p, miR-125a-5p, miR-320a, miR-320b and let-7f-5p.

It provides a method for predicting the risk of an adverse pregnancy or neonatal outcome for a pregnant subject by detecting the elevated level of bacteria from one or more selected bacterial taxa (e.g., genera or species). A kit useful for such a method is also provided. In addition, it provides a method for determining the risk of having advanced cervical dilation and/or premature cervical shortening based on differentially abundant bacterial taxa.

The invention discloses a pregnancy outcome influence factor assessment method based on a relative risk decision-making tree model. The method comprises the steps that binary digital processing is conducted on data in a national free pre-pregnant eugenic health examination item information system, then a Pg exposure value of a pre-pregnant eugenic health examination-reproductive age population exposure value multi-dimensional input matrix is obtained through establishment, and a relative risk vector RR suitable for space-time multi-dimensional condition is established according to the Pg exposure value; a pre-pregnant eugenic health examination item Examy corresponding to the maximum relative risk in the RR is selected and serves as an empty father node of the relative risk decision-making tree model TR; blade node risk factor risk serves as an empty blade node of the relative risk decision-making tree model TR. The method is applied to pregnancy outcome influence factor assessment, the assessment accuracy of pregnancy outcome influence factors and their risk factors are effectively improved, the utilization value of pre-pregnant eugenic health examination data to smart city building is improved, and the method has the important significance on promotion of social harmonious and sustainable development.

The present invention provides for methods for evaluating the risk of an adverse pregnancy outcome in a subject and methods for treating subjects evaluated as being high risk. In some aspects, the present invention provides a method of evaluating the risk of an adverse pregnancy outcome in a subject, where if the subject does have an abnormal level of AMH as compared to a predetermined normal level the subject is more likely to have an adverse pregnancy outcome, and if the subject does not have an abnormal level of AMH the subject is less likely to have an adverse pregnancy outcome. In other aspects, the present invention provides a method of determining the gender of a fetus comprising obtaining information regarding the level of AMH in a sample from a pregnant subject.

A computer implemented method of early prediction of risk of a pregnancy outcome in a pregnant woman, comprising the steps of: inputting into a computational model values for a panel of a plurality of preeclampsia specific biomarkers comprising at least one metabolite, and optionally at least one protein or clinical risk factor, selected from Table 1, in which the values are obtained from the pregnant woman early in pregnancy; selecting a subset of inputted values comprising a value for at least one metabolite and optionally at least one protein or clinical risk factor value, based on a selected pregnancy outcome selected from pre-term preeclampsia, term preeclampsia and all preeclampsia; calculating a predicted risk of the selected pregnancy outcome based on the subset of inputted values; and outputting the predicted risk of the pregnancy outcome for the pregnant woman.

There is disclosed a device for pregnancy detection is provided, the device comprising: a central main body comprising a first end and a second end; a pregnancy detection element that is mounted at an edge of the second opening, and an upper longitudinal crease and a lower longitudinal crease, wherein the device is opened by applying simultaneous pressure to the upper longitudinal crease and the lower longitudinal crease, wherein, when in operation, the first opening of the first end is configured to receive urine from a female user while the female user is in a standing position and enables the urine to pass through the pregnancy detection element, and wherein, when the urine comes in contact with the pregnancy detection element, the pregnancy detection element immunologically detects human chorionic gonadotropin (hCG) present in the urine of the female user and indicates positive pregnancy result if the female user is pregnant.

The invention discloses application of LncRNA ENST00000514235 in serum as a marker for URSA (unexplained recurrent spontaneous abortion) diagnosis and pregnancy outcome evaluation. A corresponding detection kit is developed by taking the LncRNA ENST00000514235 as the marker for URSA diagnosis and pregnancy outcome evaluation. The detection kit has the advantages of high detection sensitivity, highspecificity, convenience in detection and capability of meeting diagnosis detection requirements of patients suffering from URSA, and clinical verification shows that the diagnosis accuracy rate is high.

The invention discloses application of circ-0079591 in serum as a marker for URSA diagnosis and pregnancy outcome assessment, and develops a corresponding detection kit by using the circ-0079591 as the marker for URSA diagnosis and pregnancy outcome assessment, wherein the kit has advantages of high detection sensitivity, high specificity and convenient detection, meets the detection needs of patients requiring URSA diagnosis, and has high diagnosis accuracy through clinical verification.

The invention discloses a method for fetal urinary system malformation comprehensive evaluation. The method specifically comprises the following steps of (1) ultrasound image acquisition and evaluation; (2) interventional sampling; (3) whole genome sequencing and evaluation; (4) umbilical cord blood Cys C, beta 2-MG level determination; (5) comprehensive evaluation. The method for the fetal urinary system malformation comprehensive evaluation has the advantages that an ultrasonic imaging technology is utilized in combination with cord blood puncture DNA high-throughput sequencing, cord blood biochemical criterion CystC and beta 2-MG level determination, the three technologies are combined to comprehensively evaluating the severity degree of abnormal fetal kidney development of the structure, gene and function of the fetal kidney, people are prompted with adverse pregnancy outcome probability or postnatal surgical risk, thereby being conductive to providing complete clinical genetic counseling.

The invention discloses application of LncRNA NONHSAT167899.1 as a marker URSA diagnosis and pregnancy outcome evaluation and develops a corresponding detection kit by taking LncRNA NONHSAT167899.1 asa marker for diagnosing URSA and evaluating pregnancy outcome. The kit is high in detection sensitivity, high in specificity and convenient to detect; the detection requirements of patients with URSAcan be met; clinical experiments show that the accuracy rate of the diagnosis is high.

A method for determining the risk of an adverse pregnancy outcome for a woman is provided comprising the steps of measuring a level of TM7-H1 and optionally one or more of BVAB1, Sneathia amnii, and Prevotella cluster 2 in a vaginal sample obtained from the woman, and identifying the woman as having an increased risk for an adverse pregnancy outcome, or other adverse pregnancy outcomes, if the levels are increased compared to corresponding standard control levels. Methods for the prophylactic treatment of subjects identified as being at increased risk for an adverse pregnancy outcome are also provided.

The invention discloses a method for predicting birth weight of a full-term newborn at 21-23 weeks of pregnancy. The method comprises the following steps: S1, building a newborn weight prediction model that is EFW = 5016.51-205.71*X1+16.30*X2+102.19*X3+86.64*X4, wherein, EFW is the predicted neonatal weight in g; X1 is the accurate gestational week during the ultrasonic examination, and X2 is the body mass index (in kg/m<2>) of a pregnant woman at second trimester B-ultrasonic examination; X3 is the volume of partial thighs of a fetus at ultrasonic examination in cm<3>; and X4 is the abdominal girth (in cm) of the fetus at ultrasonic examination; S2, collecting gestational weeks and progestational body mass indexes of the pregnant woman; S3, carrying out two-dimensional ultrasonic measurement on the abdominal girth of the fetus at 21-23 weeks of pregnancy; S4, carrying out three-dimensional ultrasonic measurement on the volume of partial thighs of the fetus at 21-23 weeks of pregnancy; and S5, substituting data collected in the steps S2-S4 into the newborn weight prediction model, and calculating the predicted weight of the newborn. The method can improve the accuracy of predicting the birth weight of the full-term newborn, and be used for advancing maternal management to the second trimester, thereby scientifically improving pregnancy results.

The invention provides an image-based non-invasive evaluation method for embryo quality in a human blastocyst freezing and thawing stage, which comprises the following steps: acquiring a single static image of a thawed blastocyst and a corresponding pregnancy result, and inputting the single static image and the corresponding pregnancy result into a neural network for training to generate an evaluation model; and obtaining a single static image of a to-be-evaluated thawed blastocyst, inputting the single static image into the evaluation model, and obtaining an embryo evaluation result. The invention further relates to an image-based non-invasive evaluation system for the embryo quality in the human freeze-thaw blastocyst stage and a computer readable storage medium.

The present disclosure teaches an assay to determine the likelihood of a successful implantation of an embryo into a female subject leading to a pregnancy and a method of treatment to facilitate same. Enabled herein is an improved assisted reproduction technology protocol based on a prognostic evaluation of pregnancy outcomes and the identification of therapeutic targets. Taught herein is a composition comprising reagents required for prognostic evaluation and treatment.

The present invention relates to a method of determining the outcome of a pregnancy. More particularly, the invention relates to a method of profiling lipids in a fluid sample obtained from a female subject to assess parameters associated with a positive pregnancy outcome.

The present disclosure teaches an assay to determine the likelihood of a successful implantation of an embryo into a female subject leading to a pregnancy. Enabled herein is an improved assisted reproduction technology protocol based on a prognostic evaluation of pregnancy outcomes. Taught herein is a composition comprising reagents required for the prognostic evaluation. Taught herein are assays comprising determination of levels of the biomarkers IL-8, G-CSF and/or VEGFA in a biological fluid sample taken before embryo implantation.